Table 4.

Association between statin use and ER+ and ER tumors

Statin useER+ cases
ER cases
n = 2,067 (%)Multivariable-adjusted HR (95% CI)*n = 373 (%)Multivariable-adjusted HR (95% CI)*
All women
    Never95.1Reference94.4Reference
    Ever4.91.06 (0.85-1.32)5.61.28 (0.78-2.08)
    Current4.71.10 (0.88-1.37)4.81.16 (0.69-1.95)
Statin useER+ cases
ER cases

n = 1,315 (%)
Multivariable-adjusted HR (95% CI)*
n = 218 (%)
Multivariable-adjusted HR (95% CI)*
Duration of use among women with ≥5 y of data
Never93.6Reference90.7Reference
1-2.9 y2.60.93 (0.66-1.32)3.71.33 (0.64-2.77)
3-4.9 y1.70.98 (0.63-1.51)2.81.68 (0.72-3.92)
≥5 y2.11.24 (0.83-1.86)2.81.81 (0.75-4.36)
  • * Multivariable-adjusted models include age, hormone therapy use, diabetes, other lipid lowering drug use, and body mass index.

  • P = 0.5 from linear trend test for the effect of the duration of statin use on risk of ER+ tumor; P = 0.08 from linear trend test for the effect of the duration of statin use on risk of ER tumor.